SONM
DNA X, Inc. NASDAQ$4.89
Mkt Cap $63.6M
52w Low $2.52
6.6% of range
52w High $38.52
50d MA $4.05
200d MA $7.82
P/E (TTM)
-0.2x
EV/EBITDA
-5.6x
P/B
—
Debt/Equity
-0.8x
ROE
259.7%
P/FCF
-0.1x
RSI (14)
—
ATR (14)
—
Beta
1.72
50d MA
$4.05
200d MA
$7.82
Avg Volume
50.6K
About
DNA X, Inc. provides enterprise 5G solutions in the United States, Canada, Europe, the Middle East, and the Asia Pacific. The company offers ruggedized cell phones for task workers, which include Sonim XP10, Sonim XP5plus, Sonim XP3plus, and Sonim XP Pro; XP100 4G and XP400 5G professional rugged phones; XP Pro 5G rugged smartphones; and XP3plus 5G rugged flip phones. It also provides connected so…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 30, 2026 | AMC | 10.97 | -10.97 | -200.0% | 5.64 | +9.6% | +0.9% | -4.3% | -12.8% | -3.9% | +5.3% | -3.7% | — |
| Oct 31, 2025 | AMC | 5.40 | -3.86 | -171.5% | 11.61 | -2.2% | -1.3% | -3.2% | -0.4% | -0.9% | -1.7% | -52.6% | — |
| Aug 8, 2025 | AMC | 0.72 | -10.97 | -1623.6% | 10.98 | -0.1% | -3.9% | -8.7% | -8.3% | -3.3% | -11.5% | -3.9% | — |
| May 12, 2025 | AMC | -0.13 | 0.08 | +161.5% | 26.82 | -7.4% | -23.5% | -33.0% | -36.2% | -38.9% | -33.2% | -24.2% | — |
| Apr 2, 2025 | AMC | -0.40 | -4.34 | -984.2% | 57.60 | -9.1% | -16.6% | -43.8% | -50.3% | -53.4% | -58.1% | -51.2% | — |
| Nov 13, 2024 | AMC | -0.66 | -0.52 | +21.2% | 59.58 | +5.4% | -2.4% | -2.1% | -6.0% | -3.6% | -4.8% | +11.8% | — |
| Aug 9, 2024 | AMC | -1.41 | -1.41 | +0.0% | 53.10 | -1.0% | +5.8% | +11.9% | +8.5% | +8.5% | +0.0% | -17.6% | — |
| May 14, 2024 | AMC | -0.30 | -0.70 | -133.3% | 104.40 | -10.2% | -13.3% | -13.1% | -12.1% | -8.3% | -10.7% | +27.2% | — |
| Mar 27, 2024 | AMC | 0.10 | -0.30 | -400.0% | 121.50 | -0.7% | -9.6% | -15.3% | -11.6% | -14.5% | -12.3% | -27.6% | — |
| Nov 14, 2023 | AMC | 0.01 | 0.10 | +900.0% | 123.12 | +1.6% | +2.6% | -0.7% | +2.3% | +3.8% | -0.6% | +7.7% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 14 | B. Riley FBR | Maintains | Buy → Buy | — | $1468.98 | $1494.18 | +1.7% | +1.7% | -5.0% | +4.2% | +6.2% | +12.8% |
| Oct 31 | Oppenheimer | Downgrade | Outperform → Perform | — | $4518.00 | $4446.00 | -1.6% | -4.8% | -10.0% | -11.2% | -9.6% | -8.8% |
| Sep 11 | B. Riley | Maintains | Buy → Buy | — | $6768.00 | $6768.00 | +0.0% | +0.8% | -10.1% | -9.8% | -10.4% | -11.4% |
| Jul 18 | B. Riley FBR | Maintains | Buy → Buy | — | $24750.00 | $24714.00 | -0.1% | -2.5% | -2.4% | -5.3% | -3.1% | +1.7% |
| Jul 9 | National Securities | Upgrade | Neutral → Buy | — | $20484.00 | $21384.00 | +4.4% | +4.2% | +12.3% | +11.6% | +17.7% | +18.9% |
| Jun 10 | National Securities | Maintains | Neutral → Neutral | — | $29034.00 | $29394.00 | +1.2% | +6.2% | +4.9% | +7.0% | +8.6% | +8.9% |
| Jun 4 | Oppenheimer | Maintains | Outperform → Outperform | — | $26406.00 | $26766.00 | +1.4% | +2.1% | +14.5% | +16.6% | +10.0% | +16.8% |
Recent Filings
8-K · 4.01
!!! Very High
DNA X, Inc. -- 8-K 4.01: Auditor Change / Resignation
Baker Tilly US, LLP out, TAAD LLP in — regional to regional swap — monitor for any disclosed disagreements.
Apr 30
8-K
Unknown — 8-K Filing
SONM's acquisition of the DNA X cryptocurrency trading platform in December 2025 positions it to capture trading revenue streams, but investors should monitor integration execution and regulatory compliance risks in the volatile crypto sector.
Apr 15
NT 10-K
!!! Very High
Unknown — Late Annual Report — Distress Signal
Sonim's late annual report filing signals potential financial distress or operational challenges, creating delisting risk and making the stock significantly riskier for investors already holding or considering positions.
Apr 1
8-K · 2.01
!!! Very High
DNA X, Inc. -- 8-K 2.01: Acquisition Completed
DNA X, Inc. (SONM) completed its acquisition of DNA Holdings Venture, Inc., signaling a strategic expansion though the nominal consideration suggests a restructuring or asset combination rather than a traditional purchase.
Mar 2
8-K · 5.02
!!! Very High
DNA X, Inc. -- 8-K 5.02: Executive Change
Sonic Foundry (SONM) appointed Mike Mulica as principal executive officer and Clay Crolius as director, effective February 9, 2026, signaling a leadership transition that investors should monitor for strategic direction changes.
Feb 10
8-K · 5.02
!!! Very High
DNA X, Inc. -- 8-K 5.02: Executive Change
DNA X's CEO Peter Liu resigned effective immediately, leaving the company without permanent leadership and creating uncertainty about strategic direction and operational continuity for investors.
Feb 5
Data updated apr 27, 2026 2:25am
· Source: massive.com